Gathering the record
Relay is organizing the evidence and source boundaries.
Oxyntomodulin-derived glucagon / GLP-1 dual receptor agonist
A weight-loss and diabetes drug approved in China. It is not FDA approved in the United States.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
Multiple randomized Phase 3 trials in Chinese adults, including a 610-participant obesity trial published in NEJM and Phase 3 diabetes studies.
Its mechanism differs from GLP-1-only agents and from GIP/GLP-1 dual agonists.
Both 4 mg and 6 mg groups lost significantly more weight than placebo through 48 weeks.
The study reported sustained weight reduction and improvement in several metabolic markers.
Mazdutide has direct diabetes-treatment evidence rather than weight-only extrapolation.
This is a real country-specific approval, not a global or U.S. approval.
Approval depends on a specific manufacturer, formulation, quality system, indication, and regulator.
Risks & unknowns
Relay has not verified a clear pattern of side effects for this compound.
Evidence boundaryHuman exposure is present, but the record is not detailed enough to characterize a reliable adverse-event pattern.
The available information does not reliably show how often particular side effects occur.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundaryApproved in China for chronic weight management and type 2 diabetes; not FDA approved Generalizability beyond studied Chinese populations, cardiovascular and kidney outcomes, rare-event safety, long-term maintenance, and regulatory evidence in other regions.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Amounts reported in a human study. A studied amount is not automatically an approved dose or a recommendation for an individual.
The study enrolled Chinese adults aged 18–75 with overweight or obesity.
| Stage / period | Amount in source | Frequency |
|---|---|---|
| 48 weeks | 4 or 6 mg target groups | Once weekly |
The primary endpoint was at week 32. Target groups do not describe initiation; this trial reference does not replace jurisdiction-specific product labeling.
Mazdutide · Phase 3 weight-management trial Primary article · Methods / interventionThis reference checked Oct 20, 2026. The full-profile review date is shown at the top.This source does not establish a mixing volume or storage period for independently sourced powder. Use formulation-specific instructions; the study amount alone is not a reconstitution recipe.
Concentration = total mass ÷ final volume. The calculator performs user-entered math; it does not choose a dose or diluent.
Open concentration calculatorStarting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
A published Phase 3 trial investigated mazdutide for weight management in Chinese adults with obesity or overweight plus a related condition.
Population: Chinese adults with obesity or overweight plus a comorbidity
Design: Randomized, double-blind, placebo-controlled trial
Mechanisms
Mazdutide (IBI362; LY3305677) is an oxyntomodulin-derived dual agonist at GLP-1 and glucagon receptors. In the 610-participant GLORY-1 Phase 3 trial, treatment-policy mean weight change at week 32 was −10.09% and −12.55% for 4 mg and 6 mg versus +0.45% placebo; efficacy-estimand week-48 reductions reached −12.05% and −14.84%. The 462-participant GLORY-2 9 mg trial later reported sustained mean weight reduction at 60 weeks and cardiometabolic improvements. Phase 3 diabetes studies showed substantial HbA1c and weight reductions. China’s NMPA approved mazdutide for chronic weight management in June 2025 and type 2 diabetes in September 2025. The evidence is regionally strong but does not establish FDA approval, global generalizability, cardiovascular-event benefit, or equivalence of non-approved products.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Research reference
A reference for the studies, populations, and routes behind this profile.
Large randomized Chinese trials support weight and glycaemic outcomes, followed by country-specific approvals.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Results are consistent, while broader generalizability and outcomes trials remain incomplete.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The evidence comes from a Chinese population and a defined clinical-trial program. Regional approval and trial material do not establish FDA approval or equivalence to an independently sourced product. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Randomized, double-blind, placebo-controlled trial
Chinese adults with moderate-to-severe obesity, including a minority with type 2 diabetes
The 9 mg group had sustained clinically meaningful weight reduction and improved several cardiometabolic markers versus placebo.
Study administration: Once-weekly mazdutide 9 mg after protocol titration or placebo
Limitations: One regional trial cannot establish global benefit-risk, cardiovascular-event reduction, or long-term maintenance after treatment.
Randomized, double-blind, placebo-controlled diabetes trial
Chinese adults with type 2 diabetes
Mazdutide produced larger HbA1c reductions than placebo and simultaneous body-weight reductions.
Study administration: Once-weekly mazdutide 4 mg, 6 mg, or placebo
Limitations: The study does not establish cardiovascular outcomes or equivalence to approved therapies outside the studied population.
Randomized, double-blind, placebo-controlled trial
Chinese adults with obesity or overweight plus a comorbidity
At week 48, efficacy-estimand mean weight change was −12.05% and −14.84% versus −0.47% with placebo.
Study administration: Once-weekly mazdutide 4 mg, 6 mg, or placebo under trial protocols
Limitations: The trial was conducted in Chinese adults; outcomes, titration, and product standards cannot be assumed identical in other populations or products.
Randomized, double-blind, placebo-controlled dose-finding trial
Chinese adults with overweight or obesity
Mazdutide up to 6 mg produced robust dose-dependent weight reduction over 24 weeks.
Study administration: Multiple once-weekly mazdutide dose regimens or placebo
Limitations: Phase 2 duration was short, and the study preceded the approved Chinese product program.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-06-08 · PMID 42251595 · DOI 10.1001/jama.2026.8142
2025-12-01 · PMID 41407859
2025-09-19
2025-06-27
2025-05-25 · PMID 40421736 · DOI 10.1056/NEJMoa2411528
2023-12-08 · NCT06164873
2023-12-01 · PMID 38092790